Not currently recruiting at University of California Health
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedcompletion around
- Principal Investigator
- by Rosen Lee (ucla)
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Rosen Lee (ucla)
HS Clinical Professor, Medicine. Authored (or co-authored) 109 research publications
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Taiho Oncology, Inc.
- ID
- NCT05945823
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 66 study participants
- Last Updated